kisqali breast cancer

Release time ：Nov-16,2024

Kisqali is a pharmaceutical agent indicated for the treatment of specific breast cancer subtypes. It is commonly administered alongside hormonal therapy to mitigate or halt the proliferation of cancerous cells. The drug is predominantly utilized in the management of advanced or metastatic breast cancer that is hormone receptor-positive and HER2-negative.

Patients undergoing Kisqali treatment for breast cancer may encounter various side effects, which can range from fatigue, nausea, alopecia, weight gain, arthralgia, headaches, insomnia, diarrhea, dermatitis, and a decreased appetite, among others. While the majority of these side effects are typically mild, some individuals might develop more severe complications, such as cardiac issues, hepatic dysfunction, or pulmonary inflammation. Consequently, it is imperative for patients receiving Kisqali to undergo routine blood work and additional diagnostic tests to assess both the drug's efficacy and the presence of adverse effects.

For individuals receiving Kisqali therapy, adherence to medical guidance is crucial, and they should promptly report any new symptoms or side effects to their healthcare provider. Maintaining a healthy lifestyle, which includes a balanced diet, regular physical activity, abstaining from smoking, and moderating alcohol consumption, can aid in reducing the impact of side effects and enhancing overall well-being. Patients are advised against pregnancy during Kisqali treatment due to potential risks to the fetus. Should any questions or concerns arise regarding Kisqali therapy, patients are encouraged to seek medical counsel promptly.